About Us
Founded in 2006, ImmunArray Ltd. holds an exclusive, worldwide license from the Weizmann..
Technology
Recent understanding of the immune system extends beyond the concept of a defense system against...
Read more
ApplicationsimmunArray’s cost-effective early diagnostic and therapy monitoring technology profiles the antibody repertoire...
|
ee also diet and calories 50mg tadalafil There are no controlled data in human pregnancyUsual Adult Dose of Methadone for Opiate Withdrawal: buy cialis overnight delivery. |
Publications
An antibody profile of systemic lupus erythematosus..
Chronic rejection of a lung transplant is characterized by a profile
Organization of the autoantibody repertoire in healthy newborns
A systems immunology approach to the host-tumor...
Antigen microarrays identify unique serum autoantibody...
Integrative analysis correlates donor transcripts to recipient...
News
Previous
Next
ImmunArray™ Closes $5 Million Financing Round Exceeding Funding Goal, Presents Data at the Two Leading Immunology Meetings
Lead investor is Virginia Life Science Investments
Rehovot, Israel an...
ImmunArray Ltd announces the licensing of a portfolio of novel proteins for the diagnosis and monitoring of therapy across a range of disorders involving Acute Brain Injury
Will support additional development and collaborations with Johns Hopk...
ImmunArray Ltd Announces the Establishment of VERACIS™ Laboratory Facility
Will support development and collaborations with Johns Hopkins Univers...
IMI invests €17,4 million to develop new biomarkers for vaccine immunosafety. ImmunArray Ltd is a consortium member and will support the international initiative.
Richmond, Virginia and Rehovot, Israel
Brussels, June 18, 2012 - On M...
ImmunArray Completes First Close on Financing Round
Presents Data at American Transplant Congress (ATC) in June
Lead i...
ImmunArray Ltd Announces Promotion of D. Scott Batty MD to Chief Executive Officer
Virginia Life Sciences Investments and others add further investments ...
ImmunArray Ltd Announces Addition to Executive Management Team, Expansion of Pharma Activities and Additional Financing
Lead investor is Virginia Life Science Investments
Rehovot, Israel ...
Formulated the strategy for product launch in the US
April 2009 - Formulated the strategy for product launch in the US
ImmunArray Completes $1.2 Million Financing Round
Lead investor is Virginia Life Science Investments
Rehovot, Israel ...
Immunarray and 20/20 Genesystems
Rehovot, ISRAEL, and Rockville, MARYLAND - December 22, 2008 -- ImmunA...
Cardiovascular validation study
July 2008-Cardiovascular validation study: blinded validation test of ...
IAL graduates from the RadBiomed Incubator
February 2008 – IAL graduates from the RadBiomed Incubator; Moved to o...